Mode
Home
Research
Clinical Trials Drug Pipeline Weekly Digests
Reference
Conditions Medications
Community
Questions
Text Size
Log in / Sign up
Home › Medications › blinatumomab

blinatumomab

3 published articles · Updated continuously

Clinical Trial Landscape

Clinical Trials of blinatumomab

17 trials tracked of blinatumomab: 3 in phase 3 or 4 and 3 with published results. The most-cited published study has 349 citations.

17Trials tracked
3Phase 3 & 4
0Recruiting
3With published results
Phase distribution
Phase 3 3 Phase 2 10 Phase 1 4
  1. Phase 3 Phase 3 Trial of Blinatumomab vs Standard Chemotherapy in Pediatric Subjects With HIgh-Risk (HR) First Relapse B-precursor Acute Lymphoblastic Leukemia (ALL) Completed · 349 cited
  2. Phase 3 Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL Completed · 82 cited
  3. Phase 3 Efficacy and Safety of the BiTE Antibody Blinatumomab in Chinese Adult Subjects With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed · 11 cited
  4. Phase 2 Clinical Study With Blinatumomab in Pediatric and Adolescent Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Completed
  5. Phase 2 Confirmatory Phase II Study of Blinatumomab (MT103) in Patients With Minimal Residual Disease of B-precursor Acute Lymphoblastic Leukemia (ALL) Completed
  6. Phase 2 Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts Completed
Show 11 more trials
  1. Phase 2 Study of the BiTE® Blinatumomab (MT103) in Adult Patients With Relapsed/Refractory B-Precursor Acute Lymphoblastic Leukemia (ALL) Completed
  2. Phase 2 Study of Blinatumomab in Japanese Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia Completed
  3. Phase 2 Blinatumomab in Adults With Relapsed/Refractory Philadelphia Positive B-precursor Acute Lymphoblastic Leukemia Completed
  4. Phase 2 Blinatumomab Maintenance Following Allogeneic Hematopoietic Cell Transplantation for Patients With Acute Lymphoblastic Leukemia Completed
  5. Phase 2 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia (ALL) Completed
  6. Phase 2 Safety and Efficacy of Blinatumomab in Adults With Newly Diagnosed High-risk Diffuse Large B-Cell Lymphoma Completed
  7. Phase 2 Clinical Study With Blinatumomab in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Completed
  8. Phase 1 Study Investigating the Safety and Efficacy of Blinatumomab in Combination With Pembrolizumab in Adults With Relapsed or Refractory Diffuse Large B Cell Lymphoma (DLBCL) Completed
  9. Phase 1 Study to Investigate Intravenous Blinatumomab in Japanese Adult Participants With Newly Diagnosed Philadelphia-negative B-precursor Acute Lymphoblastic Leukemia (B-ALL) Completed
  10. Phase 1 A Phase 1b Open-Label Study Investigating the Safety and Pharmacokinetics of Administration of Subcutaneous Blinatumomab for the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma Completed
  11. Phase 1 Blinatumomab in Combination With AMG 404 for the Treatment of Adults With Relapsed or Refractory B Cell Precursor ALL Completed

Showing the 17 most-cited and recently-updated of 17 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL
Oncology RCT
Chemotherapy-Free Ponatinib Plus Blinatumomab Beats Imatinib in Ph-Positive ALL Trial shows ponatinib and blinatumomab improve outcomes for Philadelphia-positive ALL
In Ph-positive ALL, frontline ponatinib plus blinatumomab achieved 86% 24-month event-free survival versus 67% with imatinib plus chemothera…
A new combination of ponatinib and blinatumomab showed higher survival rates and fewer relapses for adults with Philadelphia-positive ALL.
Oct 15, 2026
Blinatumomab plus chemotherapy improves disease-free and overall survival in pediatric B-ALL
Hematology Meta-analysis
Blinatumomab plus chemotherapy improves disease-free and overall survival in pediatric B-ALL Trial shows blinatumomab improves survival for pediatric B-cell leukemia
This meta-analysis of randomized trials found that adding blinatumomab to chemotherapy improved disease-free survival (RR 0.63) and overall …
Adding blinatumomab to chemotherapy may improve survival rates for children with specific types of high-risk or relapsed B-cell leukemia.
Oct 1, 2026
Blinatumomab Improves Four Year Event Free Survival in Pediatric High Risk B Cell ALL
Oncology RCT
Blinatumomab Improves Four Year Event Free Survival in Pediatric High Risk B Cell ALL Trial shows blinatumomab improves survival for children with high-risk leukemia
Blinatumomab significantly improves 4-year event-free survival in children with high-risk B-cell ALL compared to standard chemotherapy.
A new trial shows that blinatumomab helps more children with high-risk B-cell leukemia stay healthy compared to standard chemotherapy.
Sep 17, 2026